Crispr Therapeutics AG (NASDAQ:CRSP) Receives $57.50 Consensus PT from Analysts

Crispr Therapeutics AG (NASDAQ:CRSP) has received a consensus rating of “Hold” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $57.50.

Several equities analysts have recently weighed in on the company. William Blair reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Tuesday, July 30th. Canaccord Genuity assumed coverage on Crispr Therapeutics in a research report on Friday, July 26th. They set a “buy” rating and a $72.00 target price on the stock. Chardan Capital reissued a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research report on Tuesday. BidaskClub downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $62.00 target price on shares of Crispr Therapeutics in a research report on Wednesday, July 31st.

NASDAQ CRSP opened at $37.91 on Wednesday. The company has a market cap of $2.07 billion, a P/E ratio of -11.02 and a beta of 3.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.96 and a current ratio of 13.96. The business’s 50 day moving average price is $43.30 and its 200-day moving average price is $43.33. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $53.90.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, July 29th. The company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.84). The company had revenue of $0.32 million for the quarter, compared to the consensus estimate of $47.57 million. Crispr Therapeutics had a negative net margin of 15,136.56% and a negative return on equity of 51.49%. The business’s revenue for the quarter was down 70.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.82) EPS. As a group, equities analysts predict that Crispr Therapeutics will post -3.85 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC grew its position in Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the last quarter. Nikko Asset Management Americas Inc. grew its position in Crispr Therapeutics by 324.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after acquiring an additional 1,430,364 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after acquiring an additional 121,176 shares during the last quarter. Wells Fargo & Company MN grew its position in Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after acquiring an additional 116,540 shares during the last quarter. Finally, Morgan Stanley grew its position in Crispr Therapeutics by 6.1% in the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock valued at $13,423,000 after acquiring an additional 16,361 shares during the last quarter. 50.23% of the stock is currently owned by institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: How the Dogs of the Dow Strategy Works

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.